Abbott and Bigfoot Biomedical have entered into an agreement to integrate the two companies’ diabetes management technology.
The companies will integrate Abbott’s FreeStyle Libre glucose sensing technology and Bigfoot’s insulin delivery system. The technology aims to ease diabetes care by eliminating the need for fingerstick calibration of glucose sensors.
Bigfoot plans to initiate a pivotal trial incorporating FreeStyle technology next year. Abbott introduced the technology in Europe in 2014 and has since made it available in more than 35 countries.
The FreeStyle Libre system is currently pending approval by the FDA.